Earlier this month, CTC attended the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, a staple of the annual medical conference calendar. From February 13 to 15, 2025 at Moscone West in San Francisco, the symposium brought together leading experts to discuss the latest advancements in GU oncology. This annual event, co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO), featured a comprehensive program of keynote presentations, panel discussions, and interactive sessions. The conference explored cutting-edge research and emerging therapies aimed at improving diagnosis, treatment, and patient management for GU cancers. ASCO GU provides an invaluable platform for healthcare professionals to learn about the latest data and engage with their colleagues. See the full 2025 program on ASCO’s website.
CTC at ASCO GU
While at ASCO GU, our team took in as many presentations and as much insight as possible. We divided our time between organizing advisory boards, running events off-site, meeting with our clients, and attending the conference proceedings to ensure we understand where the landscape is moving. We believe that by understanding the evolving treatment landscape, we can be a more effective strategic partner to our clients.
Key Takeaways from 2025 ASCO GU
Our biggest takeaway from the 2025 ASCO GU is how quickly GU oncology research is changing. There were major updates to a few of the studies and trials discussed at the ESMO Congress in Barcelona just last fall.
As advancements are made and clinical trials continue to unfold, new questions inevitably emerge. At ASCO GU, we saw firsthand how clinical trial results may answer one question but spark ten more. While this constant cycle of discovery could be seen as a challenge, we view it as a sign of progress. This is a good thing for patients. Every breakthrough may present new obstacles, but researchers push forward, tackling each new question with determination, and always keeping the patient at the centre of their thoughts.
As med comms professionals, we’re faced with the ever-present challenge of timing. By the time clinical trials conclude, their results may be difficult to interpret as the standard of care has already shifted. Conferences like ASCO GU serve as a reminder of the rapid pace of medical advancements and the complexity of medical education. We believe it’s crucial to continue to bridge the gap between emerging research and practical patient care, ensuring that clinicians have access to timely, relevant information while maintaining academic integrity.
One way to address the challenge of clinical trial timing is through the development of registries and real world data capture. As clinical trials alone may not answer every question, and the question that is answered may not be relevant anymore, real-world data is becoming increasingly valuable. However, this strategy presents its own challenges, such as the need for large, high-quality datasets, and an understanding that this type of research will never be as empirical as a well-designed clinical trial.
The CTC team remains committed to attending conferences and collaborating with healthcare professionals, key opinion leaders, and industry experts to explore innovative solutions and ensure that the latest advancements translate into real-world impact. We attend a number of events similar to ASCO GU every year. These conferences and symposiums cover a wide variety of topics, and we love sharing what we learn at each one. To keep up to date with CTC’s learnings, sign up for our newsletter!
